Ray Dalio Regeneron Pharmaceuticals, Inc. Transaction History

Bridgewater Associates, LP

$19.6 Billion
Q1 2024

A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 61,146 shares of REGN stock, worth $60.1 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares

61,146

Previous 110,132 44.48%

Holding current value

$60.1 Million

Previous $96.7 Million 39.16%

% of portfolio

0.3%

Previous 0.54%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$902.69 - $993.35 $44.2 Million - $48.7 Million	-48,986 Reduced 44.48%	61,146 $58.9 Million
Q4 2023 Feb 14, 2024	BUY	$775.18 - $881.7 $38.3 Million - $43.5 Million	49,383 Added 81.29%	110,132 $96.7 Million
Q3 2023 Nov 13, 2023	SELL	$692.45 - $844.37 $27.8 Million - $33.9 Million	-40,184 Reduced 39.81%	60,749 $50 Million
Q2 2023 Aug 11, 2023	BUY	$700.03 - $830.35 $25.2 Million - $29.9 Million	36,035 Added 55.53%	100,933 $72.5 Million
Q1 2023 May 12, 2023	BUY	$680.49 - $826.97 $17.7 Million - $21.5 Million	26,017 Added 66.91%	64,898 $53.3 Million

Q4 2022 Feb 13, 2023	SELL	$705.89 - $766.39 $13.1 Million - $14.3 Million	-18,596 Reduced 32.35%	38,881 $28.1 Million
Q3 2022 Nov 10, 2022	SELL	$573.97 - $724.32 $9.43 Million - $11.9 Million	-16,423 Reduced 22.22%	57,477 $39.6 Million
Q2 2022 Aug 11, 2022	BUY	$548.35 - $738.84 $37.5 Million - $50.6 Million	68,448 Added 1255.47%	73,900 $43.7 Million
Q1 2022 May 13, 2022	SELL	$595.12 - $698.43 $1.24 Million - $1.45 Million	-2,083 Reduced 27.64%	5,452 $3.81 Million
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $61,413 - $75,819	113 Added 1.52%	7,535 $4.76 Million
Q3 2021 Nov 12, 2021	SELL	$574.03 - $680.96 $3.02 Million - $3.58 Million	-5,263 Reduced 41.49%	7,422 $4.49 Million
Q2 2021 Aug 13, 2021	BUY	$472.8 - $558.54 $6 Million - $7.09 Million	12,685 New	12,685 $7.09 Million
Q4 2019 Feb 13, 2020	SELL	$274.13 - $376.51 $16.9 Million - $23.2 Million	-61,705 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$273.46 - $318.39 $16.2 Million - $18.9 Million	59,330 Added 2498.11%	61,705 $17.1 Million
Q2 2019 Aug 13, 2019	BUY	$299.6 - $414.82 $711,550 - $985,197	2,375 New	2,375 $743,000
Q1 2019 May 14, 2019	SELL	$372.08 - $439.57 $1.8 Million - $2.13 Million	-4,842 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$335.82 - $403.04 $2.66 Million - $3.2 Million	-7,930 Reduced 62.09%	4,842 $1.81 Million
Q3 2018 Nov 13, 2018	BUY	$351.14 - $408.51 $447,001 - $520,033	1,273 Added 11.07%	12,772 $5.16 Million
Q2 2018 Aug 13, 2018	SELL	$284.6 - $344.99 $2.95 Million - $3.58 Million	-10,373 Reduced 47.43%	11,499 $0
Q1 2018 May 15, 2018	BUY	$315.82 - $393.78 $6.91 Million - $8.61 Million	21,872 New	21,872 $7.53 Million
Q4 2017 Feb 13, 2018	SELL	$358.63 - $469.95 $9.22 Million - $12.1 Million	-25,700 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$431.38 - $504.0 $11.1 Million - $13 Million	25,700	25,700 $11.5 Million

Others Institutions Holding REGN

# of Institutions

1,428

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $105B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track Ray Dalio's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Account